Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yucan granules (愈蚕颗粒) is a Traditional Chinese Medicine (TCM) botanical drug candidate developed by Wuhan Humanwell Innovative Drug R&D and Shanghai Resurrection Stone Pharmaceutical Technology. It is currently in Phase II clinical development for the treatment of diabetic kidney disease (DKD) characterized by macroalbuminuria. The formulation is intended as an adjunct to standard-of-care therapies, including ACE inhibitors, ARBs, and glucose-lowering agents. As a TCM product, it likely functions through a multi-component, multi-target approach to alleviate renal inflammation, oxidative stress, and fibrosis, thereby reducing protein leakage and slowing the progression of kidney damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yucan granules.